Tanaka K, Hirohata T
Department of Public Health, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Fukuoka Igaku Zasshi. 1998 Aug;89(8):238-48.
The roles of hepatitis C virus (HCV) genotypes and viremia levels in the pathogenesis of hepatocellular carcinoma (HCC) were examined in case-control analyses of 69 patients with HCC, 55 patients with liver cirrhosis (LC) without HCC, and 30 controls undergoing health examinations. Major HCV genotypes (genotypes 1 and 2) were determined by both reverse transcription-polymerase chain reaction (RT-PCR)-based and serological assays, and the HCV-RNA level by a branched DNA assay. Genotype 1 was detected in 68-82% of HCCs, 71-73% of LCs, and 50-72% of controls. Based on RT-RCR, the relative risk for genotype 1 vs. 2 contrasting either HCC or LC patients with controls was estimated at 3.6 (95% confidence interval: 1.1-12.5) for HCC and 4.8 (1.1-20.4) for LC, whereas no risk excess was evident for the occurrence of HCC in LC (relative risk: 0.7). The corresponding association based on the serological assay was somewhat weaker and statistically insignificant. No significant difference in age or time lapse after blood transfusion was observed according to the genotype. The HCV-RNA titer for genotype 1 was significantly lower among HCC patients than among LC patients or controls. Genotype 1 HCV may be associated with HCC through affecting relatively early stages of liver diseases progression prior to the establishment of LC.
在一项病例对照分析中,对69例肝细胞癌(HCC)患者、55例无HCC的肝硬化(LC)患者和30例接受健康检查的对照者进行了研究,以探讨丙型肝炎病毒(HCV)基因型和病毒血症水平在HCC发病机制中的作用。主要HCV基因型(1型和2型)通过基于逆转录-聚合酶链反应(RT-PCR)的检测和血清学检测来确定,HCV-RNA水平通过分支DNA检测来测定。在68%-82%的HCC患者、71%-73%的LC患者和50%-72%的对照者中检测到1型基因型。基于RT-RCR,将HCC或LC患者与对照者进行对比时,1型基因型相对于2型基因型的相对风险在HCC患者中估计为3.6(95%置信区间:1.1-12.5),在LC患者中为4.8(1.1-20.4),而在LC患者中发生HCC时没有明显的风险增加(相对风险:0.7)。基于血清学检测的相应关联稍弱且无统计学意义。根据基因型,在年龄或输血后时间间隔方面未观察到显著差异。HCC患者中1型基因型的HCV-RNA滴度显著低于LC患者或对照者。1型HCV可能通过影响在LC形成之前肝脏疾病进展的相对早期阶段而与HCC相关。